Prometheus Biosciences Inc (RXDX)

NASDAQ
20.92
-1.22(-5.51%)
After Hours
20.93
+0.01(+0.05%)
- Real-time Data
  • Volume:
    201,683
  • Bid/Ask:
    20.35/23.50
  • Day's Range:
    20.25 - 23.28

RXDX Overview

Prev. Close
20.92
Day's Range
20.25-23.28
Revenue
760K
Open
22.22
52 wk Range
16.11-30.64
EPS
-
Volume
201,683
Market Cap
813.05M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
160,504
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
38,864,841
Next Earnings Date
Sep 01, 2021
What is your sentiment on Prometheus Biosciences Inc?
or
Market is currently closed. Voting is open during market hours.

Prometheus Biosciences Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralNeutralSellStrong SellBuy
Technical IndicatorsStrong BuyStrong BuyStrong SellStrong SellStrong Buy
SummaryBuyBuyStrong SellStrong SellStrong Buy

Prometheus Biosciences Inc Company Profile

Prometheus Biosciences Inc Company Profile

Employees
35

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. The company has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. The company was founded in 2016 and is based in San Diego, California.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.